bioethics: Case Discussion - Double Standard for an AIDS Drug

[Sanjaya.Dhakal]

>After such long gap, we have an issue now to share our views on that. The 
>issue presented "Double Standards for an AIDS Drug" by Julie Milstein is 
>very interesting.
>
>
>
>For me, it is not fair to stop licensing the medicine to the country they 
>tested if the later wants it. Experimenting on someone is okay but 
>implementing the result of the experiment on the same population is not!!! 
>For me it sounds completely unethical approach. What is the explanation 
>behind licensing must be made in the country of manufacture? Why did not 
>AFSSAPS conducted the trial in <?xml:namespace prefix = st1 ns = 
>"urn:schemas-microsoft-com:office:smarttags" />France instead of Africa?? 
>I believe that they can provide their knowledge about the drug to DRA, if 
>they are worried about t! he negative part of the drug. If still DRA finds 
>more benefits to it's population by licensing the drug, they should be 
>able to make decision on their own.
>
>
>
>With regard to second question, I think WHO made a good decision. WHO has 
>its own mechanism and team of experts to test and discuss the efficacy and 
>potential side effects of viravet. They can make their recommendation 
>believing their expert's.
>
>
>
>To avoid such awkward situation, it may be better to develop some other 
>guidelines (if it is not already there) not letting such trials to conduct 
>outside the country of manufacture.
>
>
>
>I would like to thank Julie for sharing this to us.
>
>
>
>Sanjaya Dhakal
>
>
>
>A550 Crabtree Hall,
>
>130 De Soto Street,
>
>Department of Epidemiology,
>
>University of Pittsburgh,
>
>Pittsburgh, PA 15261
>
>412 578 0285 (H)
>
>412 624 1731 (W)
>
>
>
>
>
>
>
>
>